Active surveillance is an increasingly recognized treatment option for men with low-risk prostate cancer.
Despite encouraging evidence for oncologic efficacy and reduction in morbidity, several barriers contribute to the underuse of this management strategy. Consistent selection criteria as well as identification and validation of triggers for subsequent intervention are essential. Incorporation of novel biomarkers as well as advanced imaging techniques may improve surveillance strategies by better defining eligibility as well as improving prompt detection of disease progression.
Written by:
Glass AS, Cooperberg MR, Meng MV, Carroll PR. Are you the author?
Department of Urology, University of California San Francisco, PO Box 1695, San Francisco, CA 94143-1695.
Reference: J Natl Cancer Inst Monogr. 2012;2012(45):202-6.
doi: 10.1093/jncimonographs/lgs032
PubMed Abstract
PMID: 23271774
UroToday.com Prostate Cancer Section
